Triple-Threat attack on Tough-to-Treat blood cancer
NCT ID NCT05861050
Summary
This study is testing a new combination of three drugs (glofitamab, venetoclax, and lenalidomide) for people newly diagnosed with a high-risk form of mantle cell lymphoma, a type of blood cancer. The goal is to see if this three-drug approach is safe and can keep the cancer from growing or coming back for a longer period. The trial will enroll about 50 adults to measure how well the treatment works over two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Huntsman Cancer Institute
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.